GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Ghrelin alleviates anxiety- and depression-like behaviors induced by chronic unpredictable mild stress in rodents.
Huang. Hui-Jie HJ; Zhu. Xiao-Cang XC; Han. Qiu-Qin QQ; Wang. Ya-Lin YL; Yue. Na N; Wang. Jing J; Yu. Rui R; Li. Bing B; Wu. Gen-Cheng GC; Liu. Qiong Q; Yu. Jin J
Key Findings
- Chronic peripheral ghrelin (5 nmol/kg/day) for 2 weeks eases anxiety and depression‑like behaviors in stressed mice.
- Stress raises the body’s own ghrelin and its brain receptor (GHSR) levels, suggesting a natural coping response.
- Direct brain delivery of GHRP‑6 (10 µg/rat/day) mimics ghrelin’s antidepressant effect in the forced swim and sucrose preference tests.
Practical Outcomes
- The data hint that activating the ghrelin/GHSR pathway could help mood under chronic stress, but the effective dose was given by injection into the brain, which isn’t practical for humans. Peripheral GHRP‑6 may not cross the blood‑brain barrier, so any real‑world use would need more research on delivery methods and safety. For now, biohackers should treat this as an interesting clue rather than a ready‑to‑use protocol.
Summary
In mice that were put under chronic stress, giving them ghrelin (a hormone that makes you hungry) every day for two weeks reduced signs of anxiety and depression. The stress also caused the mice’s own ghrelin system in the brain to become more active. When the researchers directly injected ghrelin or a ghrelin‑mimicking peptide called GHRP‑6 into the brain, it also lifted depressive‑like behavior.
Abstract
As a regulator of food intake, ghrelin also plays a key role in mood disorders. Previous studies reported that acute ghrelin administration defends against depressive symptoms of chronic stress. However, the effects of long-term ghrelin on rodents under chronic stress hasn't been revealed. In this study, we found chronic peripheral administration of ghrelin (5nmol/kg/day for 2 weeks, i.p.) could alleviate anxiety- and depression-like behaviors induced by chronic unpredictable mild stress (CUMS). The depression-like behaviors were assessed by the forced swimming test (FST), and anxiety-like behaviors were assessed by the open field test (OFT) and the elevated plus maze test (EPM). Meanwhile, we observed that peripheral acylated ghrelin, together with gastral and hippocampal ghrelin prepropeptide mRNA level, were significantly up-regulated in CUMS mice. Besides, the increased protein level of growth hormone secretagogue receptor (GHSR) in hippocampus were also detected. These results suggested that the endogenous ghrelin/GHSR pathway activated by CUMS plays a role in homeostasis. Further results showed that central treatment of ghrelin (10μg/rat/day for 2 weeks, i.c.v.) or GHRP-6 (the agonist of GHSR, 10μg/rat/day for 2 weeks, i.c.v.) significantly alleviated the depression-like behaviors induced by CUMS in FST and sucrose preference test (SPT). Based on these results, we concluded that central GHSR is involved in the antidepressant-like effect of exogenous ghrelin treatment, and ghrelin/GHSR may have the inherent neuromodulatory properties against depressive symptoms.
Study Information
pubmed
2017
2017-02-27T00:00:00.000Z
10.1016/j.bbr.2017.02.040
104
60